These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37013426)

  • 1. Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-release Trazodone.
    Di Nicola M; Pepe M; Panaccione I; Moccia L; Janiri L; Sani G
    Curr Neuropharmacol; 2023; 21(11):2195-2205. PubMed ID: 37013426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
    Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
    CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rediscovering trazodone for the treatment of major depressive disorder.
    Fagiolini A; Comandini A; Catena Dell'Osso M; Kasper S
    CNS Drugs; 2012 Dec; 26(12):1033-49. PubMed ID: 23192413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Trazodone Contramid® in clinical practice: personalizing antidepressant intervention].
    Fagiolini A; Amodeo G; Goracci A; Blardi P
    Riv Psichiatr; 2016; 51(4):123-128. PubMed ID: 27727261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Patient-reported Outcomes of Quality of Life and Functioning Before and After Treatment of Major Depressive Disorder Comorbid With Alcohol Use Disorders.
    Danovitch I; Steiner AJ; Kazdan A; Goldenberg M; Haglund M; Mirocha J; Collison K; Vanle B; Dang J; IsHak WW
    J Addict Med; 2017; 11(1):47-54. PubMed ID: 27763941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressants for insomnia in adults.
    Everitt H; Baldwin DS; Stuart B; Lipinska G; Mayers A; Malizia AL; Manson CC; Wilson S
    Cochrane Database Syst Rev; 2018 May; 5(5):CD010753. PubMed ID: 29761479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serotonin neurotrasmission and treatment options for depression].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):174-177. PubMed ID: 29265105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical guidance for prescribing trazodone extended-release in major depression.
    Goracci A; Forgione RN; De Giorgi R; Coluccia A; Cuomo A; Fagiolini A
    Expert Opin Pharmacother; 2016; 17(3):433-41. PubMed ID: 26678742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological treatment in alcohol-, drug- and benzodiazepine-dependent patients - the significance of trazodone].
    Funk S
    Neuropsychopharmacol Hung; 2013 Jun; 15(2):85-93. PubMed ID: 23817359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes in major depressive disorder in patients with comorbid alcohol use disorder: A STAR*D analysis.
    Tang VM; Yu D; Weissman CR; Jones BDM; Wang G; Sloan ME; Blumberger DM; Daskalakis ZJ; Le Foll B; Voineskos D
    J Affect Disord; 2023 Oct; 339():691-697. PubMed ID: 37467796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.
    Cuomo A; Ballerini A; Bruni AC; Decina P; Di Sciascio G; Fiorentini A; Scaglione F; Vampini C; Fagiolini A
    Riv Psichiatr; 2019; 54(4):137-149. PubMed ID: 31379379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
    Sheehan DV; Rozova A; Gossen ER; Gibertini M
    Psychopharmacol Bull; 2009; 42(4):5-22. PubMed ID: 20581790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action.
    Albert U; Lamba P; Stahl SM
    CNS Spectr; 2021 Jun; 26(3):232-242. PubMed ID: 33731232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant effectiveness of deep Transcranial Magnetic Stimulation (dTMS) in patients with Major Depressive Disorder (MDD) with or without Alcohol Use Disorders (AUDs): a 6-month, open label, follow-up study.
    Rapinesi C; Curto M; Kotzalidis GD; Del Casale A; Serata D; Ferri VR; Di Pietro S; Scatena P; Bersani FS; Raccah RN; Digiacomantonio V; Ferracuti S; Bersani G; Zangen A; Angeletti G; Girardi P
    J Affect Disord; 2015 Mar; 174():57-63. PubMed ID: 25484178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Trazodone--its multifunctional mechanism of action and clinical use].
    Frecska E
    Neuropsychopharmacol Hung; 2010 Dec; 12(4):477-82. PubMed ID: 21220793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of comorbid alcohol use disorder on treatment response of depressive patients.
    Hashimoto E; Tayama M; Ishikawa H; Yamamoto M; Saito T
    J Neural Transm (Vienna); 2015 Feb; 122(2):301-6. PubMed ID: 24928545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Personalized treatment of depression phenotypes: role of trazodone in depression with insomnia].
    Antonelli Incalzi R; Caraci F; Cuomo A; Fagiolini A; Ferini Strambi L
    Riv Psichiatr; 2020; 55(6):371-379. PubMed ID: 33349731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TED-trazodone effectiveness in depression: a naturalistic study of the effeciveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder.
    Dudek D; Chrobak AA; Krupa AJ; Gorostowicz A; Gerlich A; Juryk A; Siwek M
    Front Pharmacol; 2023; 14():1296639. PubMed ID: 38027034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.